×
About 873 results

ALLMedicine™ 17-hydroxyprogesterone Center

Research & Reviews  305 results

Serum LH levels are associated to serum insulin and Anti-Müllerian Hormone levels in wo...
https://doi.org/10.1111/cen.14912
Clinical Endocrinology; Makolle S, Catteau-Jonard S et. al.

Mar 14th, 2023 - The aim of the study was to investigate whether serum Luteinizing Hormone (LH) levels in women with Functional Hypothalamic Amenorrhea (FHA) and Polycystic Ovarian Morphology (PCOM) are still associated to Body Mass Index (BMI) and/or serum insuli...

17-OHPC in Pregnancy: IM vs SC Routes
https://clinicaltrials.gov/ct2/show/NCT04183452

Mar 3rd, 2023 - 17-hydroxyprogesterone caproate (17-OHPC) is used in women with a prior preterm birth (PTB) as it reduces recurrences by a third. The drug is administered intramuscularly (IM) but that creates discomfort and in many instances requires repeated off...

Establishing 17-Hydroxyprogesterone Cutoff Values for Congenital Adrenal Hyperplasia in...
https://doi.org/10.1055/a-2022-8399
Experimental and Clinical Endocrinology & Diabetes : Offi... Yoon YA, Woo S et. al.

Mar 1st, 2023 - Newborn screening for congenital adrenal hyperplasia (CAH) has benefits with a high adoption rate worldwide. It also has problems of high false positives, which can cause stress to the patient's family with economic losses and unnecessary visits o...

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
https://clinicaltrials.gov/ct2/show/NCT02574910

Feb 17th, 2023 - Congenital adrenal hyperplasia (CAH) is an inherited inability to synthesize cortisol in the adrenal gland. More than 90% of cases are cause by deficiency of steroid 21-hydroxylase (CYP21, also termed CYP21A2, P450c21), which is a cytochrome P450 ...

Clinical analysis of 78 patients with nonclassical 21-hydroxylase deficiency.
https://doi.org/10.1007/s00404-023-06946-5
Archives of Gynecology and Obstetrics; Liu E, Luo H et. al.

Feb 12th, 2023 - Retrospectively analyze the clinical characteristics of patients with nonclassical 21-hydroxylase deficiency (NC21OHD) as well as the relationship between the gene mutations and endocrine hormones. In addition, the relationship between different b...

see more →

Clinicaltrials.gov  26 results

17-OHPC in Pregnancy: IM vs SC Routes
https://clinicaltrials.gov/ct2/show/NCT04183452

Mar 3rd, 2023 - 17-hydroxyprogesterone caproate (17-OHPC) is used in women with a prior preterm birth (PTB) as it reduces recurrences by a third. The drug is administered intramuscularly (IM) but that creates discomfort and in many instances requires repeated off...

Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1
https://clinicaltrials.gov/ct2/show/NCT02574910

Feb 17th, 2023 - Congenital adrenal hyperplasia (CAH) is an inherited inability to synthesize cortisol in the adrenal gland. More than 90% of cases are cause by deficiency of steroid 21-hydroxylase (CYP21, also termed CYP21A2, P450c21), which is a cytochrome P450 ...

Androgen Reduction in Congenital Adrenal Hyperplasia
https://clinicaltrials.gov/ct2/show/NCT03548246

Feb 1st, 2023 - Congenital adrenal hyperplasia (CAH) is an inherited inability to synthesize cortisol in the adrenal gland. More than 90% of cases are cause by deficiency of steroid 21-hydroxylase (CYP21, also termed CYP21A2, P450c21), which is a cytochrome P450 ...

Time-restricted Eating to Improve Metabolic Abnormalities in Polycystic Ovarian Syndrome
https://clinicaltrials.gov/ct2/show/NCT05126199

Sep 19th, 2022 - Background: Polycystic ovarian syndrome (PCOS) is the most common reproductive endocrinopathy in women of reproductive age with many associated metabolic symptoms, in particular hyperinsulinemia, insulin resistance and a high lifetime risk of type...

Determination of the Incidence of Endometriosis and or Adenomyosis in Patients Diagnosed With Polycystic Ovary Syndrome, or the Incidence of Polycystic Ovary Syndrome in Patients Diagnosed With End...
https://clinicaltrials.gov/ct2/show/NCT04916171

Aug 11th, 2022 - For the diagnosis of polycystic ovary syndrome, Rotterdam Criteria will be used. Hyperandrogenism will be determined clinically by Ferriman-Gallwey scoring, and biochemically by serum total testosterone and sex hormone initiating globulin (SHBG). ...

see more →

News  18 results

Polycystic Ovary Syndrome: It’s Not Just About Fertility
https://www.medscape.com/viewarticle/951631

May 21st, 2021 - Polycystic ovary syndrome, the most common endocrinopathy and most common cause of female infertility, affects 8%-13% of reproductive-aged women. PCOS has a profound impact on a woman’s life yet its diagnosis and management remain confusing despit...

Polycystic ovary syndrome: It’s not just about fertility
https://www.mdedge.com/obgyn/article/240396/reproductive-endocrinology/polycystic-ovary-syndrome-its-not-just-about
Mark P. Trolice, MD

May 20th, 2021 - Polycystic ovary syndrome, the most common endocrinopathy and most common cause of female infertility, affects 8%-13% of reproductive-aged women. PCOS has a profound impact on a woman’s life yet its diagnosis and management remain confusing despit.

CBD Oil for Epilepsy Linked to Early Onset of Puberty in 2-Year-Old
https://www.medscape.com/viewarticle/950260

May 3rd, 2021 - NEW YORK (Reuters Health) - Researchers from the U.K. are reporting a case of early puberty in a 2-year-old boy who was given cannabidiol (CBD) oil his mother purchased online to help control epileptic seizures. The start of puberty before the age...

COVID-19's New Diabetes Cases; Unrefrigerated Insulin Still Stable?
https://www.medpagetoday.com/endocrinology/generalendocrinology/91083

Feb 7th, 2021 - Following a November study finding that nearly 15% of hospitalized COVID-19 patients developed diabetes, healthcare providers are carefully watching for new cases. (Diabetes, Obesity and Metabolism/The Philadelphia Inquirer) A modified-release hyd...

Call for FDA to Withdraw Preterm Birth Drug Divides Doctors and Insurers
https://www.staging.medscape.com/viewarticle/924366

Jan 28th, 2020 - Doctors fear that the only drug approved to prevent preterm birth, the nation's leading cause of infant mortality and disability, will no longer be available to expectant mothers. The drug, sold under the brand name Makena, has been in limbo since...

see more →